Biotech Startups

Probius develops Quantum Electrochemical Spectroscopy (QES), a label- and reagent-free electrochemical sensing technology that detects and quantifies thousands of analytes—proteins, metabolites, and cells—from microliter-scale biological samples in about 30 minutes. The platform generates digital representations of biological specimens and cloud-based multiplex assays intended to feed AI models of biology for biomarker discovery, drug development, and bioproduction quality control.

7 investors

Proteinea uses proprietary AI models and computational tools to engineer antibodies, focusing on rational design of antibody Fc domains for improved efficacy, half-life, and targeted biodistribution. It combines AI-driven design frameworks with wet-lab validation to develop Fc-optimized antibody scaffolds for therapeutic development.

7 investors

Qualifyze offers a centralized audit management platform for life sciences supply chains, letting quality and procurement teams plan, execute, and track supplier GxP audits globally with integrated CAPA tracking. It also provides access to a large library of ready-to-use GxP audit reports to speed up supplier qualification and compliance.

7 investors

QuantHealth provides clinical trial design optimization tools that help pharmaceutical and biotech companies evaluate trial outcomes, competitive positioning, and enrollment feasibility to reduce development risk and accelerate timelines.

7 investors

Quilt provides data management services that treat data like code, turning Amazon S3 into a versioned data hub for teams. Its offering includes a Python client, a web catalog for browsing and visualizing S3, and a CloudFormation backend for compute and identity management.

7 investors

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases. Its pipeline includes ozureprubart, a long-acting anti-IgE antibody being developed for food allergy.

7 investors

Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.

7 investors

Reverie Labs built machine learning software for pharmaceutical companies and later developed its own drug pipeline using those ML tools. The company was acquired by Ginkgo in February 2024.

7 investors

Robigo develops engineered microbial crop protection products for growers, including a biological solution targeting Sudden Death Syndrome in soybean. Its platform aims to deliver season-long yield protection against high-impact agricultural diseases while preserving beneficial organisms.

7 investors

Ruby Bio develops biosynthesis technology and scale-up solutions for specialty chemicals, biofuels, and alternative proteins. The company serves manufacturers and food producers seeking sustainable, bio-derived alternatives to traditional chemical and protein sources.

7 investors

SciRhom is a biotech company developing first-in-class humanized antibodies against iRhom2, which regulates the enzyme TACE/ADAM17 to block pro-inflammatory signaling pathways. Its pipeline targets autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

7 investors

Sequana Medical develops the alfapump system and DSR therapy for treating fluid overload in patients with conditions such as liver disease and heart failure. It is a publicly listed medical device company addressing unmet needs in the management of ascites and related conditions.

7 investors

SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.

7 investors

Shellworks develops VIVOMER, a compostable material made by collaborating with microorganisms that produce natural polymers, designed to perform like plastic but break down without leaving waste. The company works with manufacturers using existing infrastructure to replace conventional permanent plastics.

7 investors

ShennonBio develops immunotherapy technologies using microfluidic engineering, computational biology, and immunology to advance T cell engineering for cancer treatment. The company serves therapeutic development organizations working on cell and gene therapies.

7 investors

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.

7 investors

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

7 investors

Sinaptica is a medical device company developing noninvasive brain modulation therapies for Alzheimer's disease, led by scientific experts and experienced medtech executives.

7 investors

SOSV is a venture capital firm that provides pre-seed funding (up to $550,000) to founders in deep technology sectors including life sciences, robotics, industrial automation, energy transition, and medical technology. The firm operates accelerator programs in New York City, San Francisco, and Newark, NJ, and does not invest in enterprise software, fintech, blockchain, crypto, cybersecurity, or ecommerce.

7 investors

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.

7 investors

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

7 investors

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.

7 investors

Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems. The company serves life science researchers globally seeking more efficient and reproducible research capabilities.

7 investors

Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.

7 investors